| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| CURIS INC | Head of Research & Development | Employee stock option (right to buy) | 350K | $4.07M | $11.62 | Jan 20, 2023 | Direct |
| Indaptus Therapeutics, Inc. | Director | Stock Option (right to buy) | 12.5K | Jun 6, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| INDP | Indaptus Therapeutics, Inc. | Jun 6, 2024 | 1 | $0 | 4 | Jun 7, 2024 | Director |
| INDP | Indaptus Therapeutics, Inc. | Feb 13, 2023 | 1 | $0 | 4 | Feb 14, 2023 | Director |
| INDP | Indaptus Therapeutics, Inc. | Feb 13, 2023 | 0 | $0 | 3 | Feb 14, 2023 | Director |
| CRIS | CURIS INC | Jan 20, 2023 | 1 | $0 | 4 | Jan 24, 2023 | Head of Research & Development |
| CRIS | CURIS INC | Jan 29, 2022 | 1 | $0 | 4 | Jan 31, 2022 | Head of Research & Development |